Health Care Select Sector SPDR® ETF

Most Recent

  • How Can Changing Demographics Impact Investors?
    Macroeconomic Analysis

    How Can Changing Demographics Impact Investors?

    Changing demographics impact investors in many ways. The demand for bonds could increase, putting downward pressure on yields.

    By Rick Rieder
  • How Does Aetna Compare to Its Peers in Medical Care Ratio?
    Company & Industry Overviews

    How Does Aetna Compare to Its Peers in Medical Care Ratio?

    The medical care ratio of health insurance companies is calculated as the ratio of the total money spent in health care claims to premiums earned.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Teva Can Benefit by Acquiring Allergan Generics

    The combined Teva–Allergan generics entity should have approximately 320 Abbreviated New Drug Applications (or ANDAs), including 110 first-to-file ANDAs (or FTF) in the US.

    By Margaret Patrick
  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Animal Health Segment

    The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.

    By Mike Benson
  • uploads///Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.

    By Mike Benson
  • uploads///goldcboe
    Company & Industry Overviews

    How Stocks and Bonds Reacted to Trump’s Victory

    The CBOE Volatility Index suddenly rose 6.0% on November 9, 2016, after it was clear that Trump had unexpectedly clinched the election.

    By Russ Koesterich, CFA
  • uploads///GEVA ALXN LAL D
    Miscellaneous

    Backing Out of the Synageva BioPharma Deal, Part 3

    Things like acts of war and natural disasters aren’t MACS unless they disproportionately affect Synageva relative to other early-clinical-stage biopharmaceutical companies.

    By Brent Nyitray, CFA, MBA
  • uploads///RAD_WBA comps
    Miscellaneous

    Could the Rite Aid–Walgreens Merger Get Competitive?

    In the Rite Aid–Walgreens merger, Walgreens is paying about 0.6x trailing-12-month revenues and 13.6x trailing-12-month EBITDA.

    By Brent Nyitray, CFA, MBA
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Lilly’s Total Returns Are Lower than Some Pharma ETFs

    The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts’ Recommendations for Merck in 2017?

    For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

    By Margaret Patrick
  • uploads///Article
    Company & Industry Overviews

    Sanofi Increased Net Revenues in 2014

    Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Think about Bristol-Myers Squibb

    Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analysts’ Recommendations for Anthem in 2017

    Based on the company’s performance in 1Q17, Anthem (ANTM) has increased its 2017 revenue guidance by around $1.5 billion.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What’s UnitedHealth Group’s outlook for 2015?

    It’s projected that UnitedHealth Group’s revenue and earnings growth in 2015 will be driven by the strong performance of the Optum segments.

    By Margaret Patrick
  • uploads///Article
    Earnings Report

    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15

    Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Enrollments decreased in UnitedHealth’s international business

    In the US, the private health insurance industry has been expanding its footprint in international markets. International markets are less penetrated and competitive.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    UnitedHealth Group’s Optum segment: Earnings rose in 2014

    UnitedHealth Group (UNH) operates Optum. It provides health services like health technology, health and well-being, and pharmacy services.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///Corporate Tax Rate of Various Countries
    Financials

    Bernstein: Tax Reform Is Bullish for the Equity Market

    Tax reform On December 2, 2017, the Senate passed Donald Trump’s tax reform bill, and on December 20, 2017, the House of Representatives passed the bill. Afterwards, the S&P 500 (SPX-INDEX) (SPY) rose to a record high. Richard Bernstein on tax reform In an interview with CNBC, prominent investor Richard Bernstein stated that tax reform could be very helpful for […]

    By Sarah Sands
  • uploads///PIMCO sector allocation
    Macroeconomic Analysis

    Turn to Financials and Healthcare When Fears of Rate Hike Loom

    With classic safe havens providing little protection, turn to financials and healthcare sectors for opportunities. Healthcare stocks usually hold up well in the run-up to a rate hike.

    By Russ Koesterich, CFA
  • uploads///Part  Graph
    Company & Industry Overviews

    Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings

    Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.

    By Peter Neil
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///XLU
    Energy & Utilities

    Utility Sector: Will Investors Continue Their Defensive Positions?

    The Utilities Select Sector SPDR ETF (XLU), which tracks the performance of the utility sector, rose 2.7% in November 2017.

    By Sarah Sands
  • uploads///HUM
    Fund Managers

    Eminence Capital Reduces Position in Humana

    During the fourth quarter of 2014, Eminence Capital lowered its stake in Humana (HUM). The company accounted for 1.33% of the fund’s 4Q14 portfolio.

    By Diana Key
  • uploads///Biogen Analysts Recommendation
    Company & Industry Overviews

    What Analysts Recommend for Biogen in June 2017

    In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Humana’s core business: The Medicare Advantage program

    Humana’s total enrollment is mainly enrollments in the MA program, a substitute for the original Medicare program, via private insurance companies.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///Tysabri revenues
    Earnings Report

    How 3Q17 Shaped up for Tysabri, Fampyra, and Zinbryta

    Tysabri revenue trends In 3Q17, Biogen’s (BIIB) Tysabri generated revenue of ~$469 million, which reflected a ~9% fall YoY (year-over-year) and a ~5% fall QoQ (quarter-over-quarter). In 3Q17, Tysabri generated US revenue of ~$267 million, which reflected an ~11% fall YoY and an ~8% fall QoQ. In 3Q17, outside the US market, Tysabri reported revenue of ~$203 […]

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    How Biogen’s Tysabri and Zinbryta Performed in 1Q17

    In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.

    By Margaret Patrick
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Teva Stock Has Risen Significantly since November Lows: What’s Next?

    On January 5, 2018, Teva Pharmaceuticals (TEVA) closed at $19.2 per share, which was ~77% higher than its 52-week low of $10.8 reported on November 2, 2017.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    Venclexta Witnessed Healthy Demand Trends in 1Q17

    AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.

    By Margaret Patrick
  • uploads///STOCK PRICE
    Earnings Report

    How Has Medtronic’s Stock Performed Recently?

    Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.

    By Sarah Collins
  • uploads///Graph
    Macroeconomic Analysis

    Assessing the economy’s impact on national healthcare spending

    National healthcare spending is a major driver of the hospital industry. National spending on hospital care is expected to amount to $973 million.

    By Margaret Patrick
  • uploads///Tracking error in the VNQ ETF tracking the RMZ Index
    Healthcare

    Comparing ETNs with ETFs: The must-know pros of ETNs

    ETNs are free of tracking errors, and investors can defer taxation until they mature or are sold.

    By Surbhi Jain
  • uploads///XAL over
    Healthcare

    Merger must-knows: The shareholder vote and 90% tender condition

    Once the SEC approves the proxy, a vote is scheduled. Usually, the last condition for a deal is the vote of the target shareholders.

    By Brent Nyitray, CFA, MBA
  • uploads///kyle sterk  unsplash
    Company & Industry Overviews

    ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain

    On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.

    By Sarah Collins
  • uploads///CI ANTM EPS accretion
    Miscellaneous

    Is the Cigna–Anthem Merger a Setup?

    The Cigna–Anthem merger deal will be subject to all sorts of headlines that will affect the spread. You can make a decent return trading around the position by keeping your head .

    By Brent Nyitray, CFA, MBA
  • Healthcare

    Third Point Partners ups stake in Amgen

    The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”

    By Samantha Nielson
  • uploads///CI ANTM downside
    Miscellaneous

    The Risk-to-Reward Ratio of the Cigna–Anthem Merger

    If the Cigna–Anthem merger closes, you end up making about $35 a share. If the deal breaks, then you would have to cover at $52 a share.

    By Brent Nyitray, CFA, MBA
  • uploads///The life expectancy has increased over the years
    Healthcare

    Increased Life Expectancy Means A Longer Investment Horizon

    Increased life expectancy means a longer investment horizon. With life expectancy increasing, young investors should invest in equities aggressively.

    By BlackRock
  • uploads///DIABETES
    Earnings Report

    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

    By Sarah Collins
  • uploads///AGN PFE PFE basics
    Miscellaneous

    Allergan–Pfizer merger: What Does Pfizer Make besides Viagra?

    The Allergan–Pfizer merger will change Pfizer’s domicile to Dublin, Ireland, and allow them to gain access to overseas cash without a US repatriation tax.

    By Brent Nyitray, CFA, MBA
  • uploads///Utilities and Telecom Sectors Have the Highest Leverage
    Macroeconomic Analysis

    How a Rate Hike Could Affect High-Leverage Sectors

    Industrials, utilities, and telecommunications have much higher leverage, as these sectors have massive capital needs.

    By Heidi Richardson
  • uploads///minimed g launch dynamics
    Company & Industry Overviews

    Diabetes Management Breakthrough: Medtronic’s MiniMed 670G

    On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings

    Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

    By Peter Neil
  • uploads///Emend Temodar Revenues
    Company & Industry Overviews

    How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017

    In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

    By Daniel Collins
  • uploads///SLXP VRX SLXP basics
    Miscellaneous

    The Salix–Valeant merger: Basics of Salix Pharmaceuticals

    Xifaxin is by far Salix’s largest product, accounting for ~70% of its revenues in 2013. Xifaxin is a big reason for the Salix–Valeant merger transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///RAD_WBA market shares
    Miscellaneous

    Can the Walgreens-Rite Aid Merger Get Antitrust Approval?

    The Walgreens-Rite Aid merger is a combination of the first and third largest pharmacies in the United States.

    By Brent Nyitray, CFA, MBA
  • uploads///share price on Oct
    Earnings Report

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.

    By Sarah Collins
  • uploads///Neuroscience
    Earnings Report

    Bristol-Myers Squibb’s Neuroscience and Immunoscience Segments

    Sales for Bristol-Myers Squibb’s (BMY) neuroscience segment declined over 80% in 2Q15, while the immunoscience segment’s sales improved ~15% in 2Q15 as compared to 2Q14.

    By Mike Benson
  • uploads///stock price
    Company & Industry Overviews

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

    By Sarah Collins
  • uploads///HUM AET downside
    Miscellaneous

    What Is the Risk-to-Reward Ratio of the Humana–Aetna Deal?

    Scenario analysis  In the risk-arbitrage world, a 12.2% expected return means a deal that has a lot of risk. Arbitrageurs sometimes refer to risk as “hair.” This deal is guaranteed a second request, and the regulators may simply be unable to get comfortable with the transaction, no matter what the companies offer in the way […]

    By Brent Nyitray, CFA, MBA
  • uploads///dna _
    Company & Industry Overviews

    European Medicines Agency Validates Merck’s Keytruda Combo

    Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

    By Mike Benson
  • uploads///DIABETES
    Company & Industry Overviews

    Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug

    On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.

    By Sarah Collins
  • uploads///RD
    Company & Industry Overviews

    What Were Pfizer’s Major Achievements in 2016?

    During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

    By Jillian Dabney
  • uploads///SLXP VRX SLXP at a glance
    Miscellaneous

    Parsing the Salix–Valeant merger MAC clause: Part 1

    In the deal between Salix Pharmaceuticals and Valeant, the MAC clause lays out the circumstances under which Valeant can back out of its deal with Salix.

    By Brent Nyitray, CFA, MBA
  • uploads///SLXP VRX GI
    Miscellaneous

    Parsing the Salix–Valeant merger MAC clause: Part 2

    Pretty much anything that has a material adverse effect on the company will be considered a MAC, but there will be exceptions to that rule.

    By Brent Nyitray, CFA, MBA
  • uploads///Munis care
    Macroeconomic Analysis

    Municipal Bonds Help You Care For Communities

    Municipal bond issuers are state-wide and local. They typically use the funds they accumulate through issuing bonds for infrastructure projects.

    By Peter Hayes
  • uploads///PCYC ABBV ABBV basics
    Miscellaneous

    The Pharmacyclics–AbbVie Merger: The Basics of AbbVie

    A major reason for the Pharmacyclics–AbbVie merger is to diversify AbbVie away from its reliance on a single product, Humira, and boost its pipeline.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Macroeconomic Analysis

    What do falling oil prices mean for the hospital industry?

    Economic conditions like falling oil prices affect the healthcare industry with a lag. This makes the hospital industry a good investment option.

    By Margaret Patrick
  • uploads///becdaabdacaceddd
    Earnings Report

    Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings

    Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

    By Mike Benson
  • uploads///US Non Farm Payrolls in May
    Macroeconomic Analysis

    Why the US Non-Farm Payroll in May Has Many Concerned

    The US May jobs report indicated weak improvement in the US labor market.

    By Sarah Sands
  • uploads///Dupixent
    Company & Industry Overviews

    Regeneron’s Dupixent Approved for Atopic Dermatitis

    In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

    By Daniel Collins
  • uploads///Graph
    Macroeconomic Analysis

    Must-read: Is the US hospital industry truly non-cyclical?

    The hospital sector is widely considered a non-cyclical or defensive industry, meaning demand for hospital services doesn’t change with the economic cycle.

    By Margaret Patrick
  • uploads///patent cliff
    Company & Industry Overviews

    Drug Patent Expirations: $190 Billion Is Up for Grabs

    According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.

    By VanEck
  • uploads///CI ANTM downside
    Miscellaneous

    Is the Cigna-Anthem Merger a Setup?

    Cigna has been put ‘in play,’ which means other buyers will be taking a look. The spread is wide, but there are major unanswered questions. It makes sense to give this one a wide berth.

    By Brent Nyitray, CFA, MBA
  • uploads///CI ANTM combination
    Miscellaneous

    Anthem Files Bear Hug Letter for Cigna on June 21

    On June 21, Anthem (ANTM) filed a bear hug letter for Cigna (CI). A bear hug letter is a formal press release in which an acquiring company discloses its interest in a target company.

    By Brent Nyitray, CFA, MBA
  • uploads///Graph
    Miscellaneous

    Negative Sentiment Will Impact Health Insurance Companies

    The healthcare bill’s failure had a negative impact on investor sentiment for health insurance carriers.

    By Margaret Patrick
  • uploads///Graph
    Miscellaneous

    FDA Granted Breakthrough Therapy Status to Merck’s HCV Therapy

    The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.

    By Margaret Patrick
  • uploads///virus _
    Earnings Report

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.

    By Mike Benson
  • uploads///SLXP VRX SLXP products
    Miscellaneous

    The Salix–Valeant merger MAC clause: Part 3

    If these carve-outs affect Salix in a disproportionate way compared to other pharma companies, then it is still a MAC and Valeant can back out of the deal.

    By Brent Nyitray, CFA, MBA
  • Financials

    Key differences between PCE and CPI as inflation measures

    The CPI and PCE are both important indicators of U.S. inflation. CPI is more important from an individual perspective, while PCE is more important for monetary policy.

    By Shelly Vinson
  • uploads///family insurance _
    Company & Industry Overviews

    UnitedHealth Group Stock at 52-Week High, Up 22% Year-to-Date

    UnitedHealth Group (UNH) stock registered its 52-week high of $270.17 last week on August 30.

    By Sarah Collins
  • uploads///Strensiq
    Earnings Report

    How Alexion Plans to Fuel Strensiq Sales

    With the Enobia acquisition in February 2012, Alexion benefited in long-term disease awareness, diagnostic planning, and initiatives in the HPP space.

    By Jillian Dabney
  • uploads///Earnings impact of Tax Reform
    Fund Managers

    Will Tax Reform Hurt Health Care Sector?

    The health care sector played an important role in the recent bull market (SPX-INDEX) rally.

    By Sarah Sands
  • uploads///US Non Farm Payrolls in August
    Macroeconomic Analysis

    Will the August Jobs Report Soften the Fed’s Rate Hike Urgency?

    During the Jackson Hole Symposium, the Federal Reserve chair, Janet Yellen, already hinted that if the August jobs report provided a strong performance, there was a chance for a rate hike during its September 2016 meeting.

    By Sarah Sands
  • uploads///medical device segment
    Company & Industry Overviews

    Abbott’s Freestyle Libre Gets Reimbursement Approval in France

    Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.

    By Sarah Collins
  • uploads///Graph
    Earnings Report

    Exploring payer mix trends at HCA Holdings

    In terms of payer mix, the percentage of HCA Holdings revenues contributed by Medicare rose from 28.0% in 3Q13 to 30.3% in 3Q14.

    By Margaret Patrick
  • uploads///Valeant
    Fund Managers

    What Bill Miller Thinks about Valeant Pharmaceuticals

    According to Bill Miller, Valeant Pharmaceuticals (VRX) is correctly valued.

    By Sarah Sands
  • uploads///Article
    Company & Industry Overviews

    Understanding Johnson & Johnson’s Ownership Structure

    As of January 2015, Johnson & Johnson’s ownership structure is dominated by passive investments. They account for more than 80% of the total ownership structure.

    By Mike Benson
  • uploads/// US Household saving rate
    Real Insights

    Mounting Evidence of Inflation Firming Up

    The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index jumped to a 14-year high…

    By VanEck
  • uploads///people _
    Financials

    Why Envision Healthcare Stock Rose ~2.4% Last Week

    Healthcare service provider Envision Healthcare (EVHC) announced its agreement to be acquired by KKR (KKR) last week.

    By Mike Benson
  • uploads///BlackRock U
    Macroeconomic Analysis

    Solid Jobs Growth Points to US Economic Health

    Solid employment growth seems to point to the improving health of the US economy. The US markets cheered the April jobs market report on Friday, May 8, 2015.

    By Rick Rieder
  • cpi componentspngautocompresscformatandixlibphp
    Consumer

    Must-know fundamentals about the US Consumer Price Index

    The Bureau of Labor Statistics (or BLS) developed the U.S. CPI in 1913 to measure the change in prices.

    By Shelly Vinson
  • pce headline corepngautocompresscformatandixlibphp
    Financials

    Why personal consumption expenditure is important to investors

    The U.S. Bureau of Economic Analysis issues PCE data, and the price index is a measure of the average increase in prices for all domestic personal consumption.

    By Shelly Vinson
  • uploads///Analysts recommendation
    Company & Industry Overviews

    Analysts Recommendations for AbbVie in August 2017

    Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Why Eli Lilly Expects 2Q17 Revenue Growth

    As per analysts’ estimates, Eli Lilly’s (LLY) revenues could rise ~3.6% to $5.6 billion in 2Q17.

    By Mike Benson
  • uploads///GUIDANCE
    Company & Industry Overviews

    How’s Gilead Sciences Expected to Perform in 2016?

    Gilead Sciences lowered its guidance for fiscal 2016 due to weak 2Q16 results reported on July 25. It expects its 2016 revenues to be $29.5 billion–$30.5 billion.

    By Sarah Collins
  • uploads///SPDR Mar
    Macroeconomic Analysis

    Gold SPDRs Fall as US Fed Members Turn Hawkish in Rate Hikes

    Gold prices retreated following the rise in the US dollar index. Gold had been gaining traction earlier last week following a dovish report by Janet Yellen, the US Federal Reserve chairperson.

    By David Meyer
  • uploads///Graph
    Earnings Report

    What Biogen Is Doing that Put It in Good Favor with Analysts

    Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Cardiovascular Products Have Been Faring

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

    By Mike Benson
  • uploads///Graph
    Macroeconomic Analysis

    The health insurance marketplace affects the hospital industry

    These exchanges—also called “health insurance marketplaces”—sell federally regulated, subsidized health insurance to individuals and small businesses.

    By Margaret Patrick
  • uploads///microbiology _
    Company & Industry Overviews

    Illumina Stock Continues Its Bull Run

    Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.

    By Sarah Collins
  • uploads///Costs
    Earnings Report

    Johnson & Johnson’s Profitability Improves in 2Q15

    Johnson & Johnson’s net profit margin improved to 25.4% for 2Q15 compared to 22.2% for 2Q14 due to the divestiture of some low profitability products and improved sales of high profitability products.

    By Mike Benson
  • uploads///Leading index
    Macroeconomic Analysis

    Why a September Rate Liftoff Seems Likely

    Atlanta Fed president Dennis Lockhart recently stated that it would take “significant deterioration in data” for him to reject the idea of a September rate hike.

    By Jeffrey Rosenberg
  • uploads///US Non Farm Payrolls in January
    Macroeconomic Analysis

    Did the January Jobs Report Improve Confidence in the US Economy?

    The January jobs report indicated a strong improvement in the labor market.

    By Sarah Sands
  • uploads///STOCK PRICE
    Earnings Report

    Understanding JNJ’s Latest Stock Price Rise

    On July 20, 2017, JNJ stock was trading at its 52-week high of $137.1, which was ~25.4% above its 52-week low of $109.3 on December 7, 2016.

    By Sarah Collins
  • uploads///highlights
    Company & Industry Overviews

    Behind JNJ’s Recent Stock Price Performance: Is More Growth Coming?

    Johnson & Johnson (JNJ) has seen a few disappointing quarterly performances, but on October 17, when JNJ announced its 3Q17 results, the stock gained 3.4%.

    By Sarah Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.